DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Dextrose is a monosaccharide that provides calories and serves as a source of energy. Sodium chloride provides electrolytes to maintain osmolality and fluid balance.
| Metabolism | Dextrose is metabolized via glycolysis and the citric acid cycle to produce ATP. Sodium chloride is not metabolized; it is excreted renally. |
| Excretion | Dextrose is metabolized to carbon dioxide and water; sodium and chloride are excreted renally. >90% of water and electrolytes are eliminated via kidneys. Minimal fecal or biliary elimination. |
| Half-life | Dextrose: not applicable (endogenous substrate). Sodium: 10-20 minutes (rapid distribution); chloride parallels sodium. Clinical context: renal function prolongs half-life of infused components. |
| Protein binding | Dextrose: negligible. Sodium: negligible (<5%). Chloride: negligible. No significant protein binding. |
| Volume of Distribution | Dextrose: 0.2-0.3 L/kg (total body water). Sodium: 0.6-0.7 L/kg (extracellular fluid). Chloride: similar to sodium. Clinical meaning: reflects distribution into extracellular space. |
| Bioavailability | Intravenous: 100%. Not applicable for other routes. |
| Onset of Action | Intravenous: immediate for volume expansion. Hyperglycemic effect within minutes. Electrolyte effects minutes to hours depending on infusion rate. |
| Duration of Action | Volume effect: 30-60 minutes after infusion stops. Caloric effect: duration depends on metabolic demand, usually 1-2 hours. Electrolyte effects persist until renal excretion. |
| Molecular Weight | Dextrose: 180.16 Da; Sodium chloride: 58.44 Da |
Intravenous infusion; rate determined by fluid and electrolyte needs; typical adult rate 100-200 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: use with caution; monitor fluid and electrolyte status; reduce infusion rate to avoid volume overload. |
| Liver impairment | No specific adjustment required for Child-Pugh classification; monitor for fluid retention. |
| Pediatric use | Weight-based dosing: 5-20 mL/kg/day as maintenance fluid; adjust based on age, weight, and clinical condition. |
| Geriatric use | Caution with volume overload; initiate at lower infusion rates (50-100 mL/hour) and monitor cardiopulmonary status. |
| 1st trimester | Safe; dextrose and sodium chloride are essential nutrients and electrolytes; used for fluid and electrolyte replacement. |
| 2nd trimester | Safe; same rationale as T1; monitor for fluid overload and electrolyte imbalances. |
| 3rd trimester | Safe; use with caution in preeclampsia or impaired renal function due to risk of fluid overload. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Dextrose and sodium chloride freely cross the placenta; concentrations equilibrate between maternal and fetal compartments. |
| Breastfeeding | Excreted into breast milk in negligible amounts; considered compatible with breastfeeding. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Dextrose 10% and sodium chloride 0.9% are normal constituents of blood and are not teratogenic. No increased risk of fetal malformations is expected when used as clinically indicated in any trimester. However, maternal hyperglycemia (from excessive dextrose administration) may cause fetal hyperinsulinism and neonatal hypoglycemia if given near term. |
| Fetal Monitoring | Monitor maternal blood glucose, serum electrolytes (especially sodium), fluid balance (input/output), and signs of fluid overload (e.g., edema, pulmonary congestion). Fetal monitoring includes fetal heart rate and uterine activity if administered during labor. In pregnancy, monitor for maternal hyperglycemia and neonatal hypoglycemia after delivery if high doses are used. |
| Fertility Effects | No known adverse effects on fertility. Dextrose and sodium chloride are essential nutrients and electrolytes; no reproductive toxicity reported at clinically relevant doses. |
■ FDA Black Box Warning
None.
| Common Effects | fluid replacement |
| Serious Effects |
Hypertonic conditions (e.g., hypernatremia, hyperglycemia with hyperosmolar coma)Severe fluid overload (e.g., pulmonary edema, congestive heart failure)Severe electrolyte disorders (e.g., hyperchloremia, hypernatremia)Known hypersensitivity to corn-derived products (for dextrose)
| Precautions | Hyperglycemia in patients with diabetes mellitus or glucose intolerance, Fluid overload in patients with cardiac or renal impairment, Electrolyte abnormalities such as hypernatremia or hyponatremia, Extravasation risk with peripheral administration, Monitor serum glucose and electrolytes regularly |
| Food/Dietary | No significant food interactions, but patients on a salt-restricted diet or with diabetes should monitor sodium and sugar intake closely per physician guidance. |
| Clinical Pearls | This combination is isotonic and provides 170 kcal/L. Use with caution in patients with heart failure, renal impairment, or hypernatremia. Monitor serum sodium and glucose levels, especially in patients with diabetes or hyperglycemia. Not suitable for resuscitation unless combined with colloid or blood products. |
| Patient Advice | This IV solution provides water, sugar, and salt to maintain hydration and electrolyte balance. · Tell your doctor if you have kidney disease, heart failure, diabetes, or high blood pressure. · Report any swelling, shortness of breath, or rapid weight gain during treatment. · Do not consume additional salt or sugar without medical advice while receiving this solution. |
Loading safety data…